Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acquired | Acquired

Total Raised




About Semma Therapeutics

Semma Therapeutics is a biopharmaceutical company developing Stem Cell-derived Islet therapy for type 1 diabetes.

Semma Therapeutics Headquarters Location

100 Technology Square Floor 3

Cambridge, Massachusetts, 02139,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Semma Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Semma Therapeutics is included in 3 Expert Collections, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



1,750 items

Semma Therapeutics Patents

Semma Therapeutics has filed 4 patents.

The 3 most popular patent topics include:

  • Cell biology
  • Diabetes
  • Stem cells
patents chart

Application Date

Grant Date


Related Topics



Autosomal recessive disorders, Rare diseases, Amino acid metabolism disorders, Aquatic ecology, Cell biology


Application Date


Grant Date


Related Topics

Autosomal recessive disorders, Rare diseases, Amino acid metabolism disorders, Aquatic ecology, Cell biology



Latest Semma Therapeutics News

Vertex acquires another maker of potentially curative diabetes treatments

Jul 11, 2022

Published July 11, 2022 Dive Brief: For the second time, Vertex is shelling out hundreds of millions of dollars to acquire a potentially curative treatment for Type 1 diabetes. Announced Monday, the deal would have Vertex pay $320 million for ViaCyte, a privately held, San Diego-based developer of stem cell-derived therapies for the disease. The purchase comes almost three years after Vertex agreed to spend almost $1 billion to acquire Semma Therapeutics, another biotechnology company attempting to effectively cure Type 1 diabetes with stem cell-based medicines. One of Semma’s programs, dubbed VX-880, is currently in human testing. Vertex said the ViaCyte deal provides “complementary assets, capabilities and technologies” to the ones it picked up through the Semma deal, including manufacturing facilities that could help accelerate its existing Type 1 diabetes programs. Vertex expects the acquisition to close later this year, provided that it gets a sign off from antitrust regulators. Dive Insight: Historically, Vertex has been best known for its work in cystic fibrosis, bringing four so-called “small molecule” drugs to market that, last quarter alone, collectively generated more than $2 billion in revenue. But with Vertex now offering treatment options for an estimated 90% of the cystic fibrosis population, investors have wondered what research areas the company will branch into to find new growth. In a note to clients, analysts at the investment firm Stifel wrote that the ViaCyte deal reflects Vertex’s commitment to cell therapy. They point out how ViaCyte, which was founded in 1999 under the name Novocell, has decades of experience in the space and a “strong” intellectual property position. ViaCyte also has collaborations in place with both device makers and CRISPR Therapeutics, a gene-editing biotech that has for years been partnering with Vertex on a possible cure for two blood disorders. What’s more, ViaCyte has ushered multiple programs into human testing. The resulting data that it’s collected “could be highly informative and valuable to really anyone working in this area,” according to Stifel analyst Paul Matteis. Yet, Matteis notes that he and his team still view the ViaCyte deal as surprising, given Vertex has framed the assets from its Semma acquisition as best-in-class. They also see the deal as “very high risk,” due to some of the challenges inherent to creating these kinds of therapies. To be effective, a cell therapy for Type 1 diabetes must not only be able to restore insulin production but also avoid triggering a response from the body’s immune system. That presents “complex” problems for cell and device engineers, according to Matteis, and it may be some time before they’re ironed out. One strategy employed by ViaCyte has been to suppress patients’ immune systems so that engineered cells can properly engraft. But the Stifel team, after speaking with “key opinion leaders,” argues that developers can’t rely on chronic immunosuppression if they want to create a “commercially compelling” cell therapy for Type 1 diabetes. To Jefferies analyst Michael Yee, the asset that pushed Vertex to acquire ViaCyte is the partnered program with CRISPR. Known as VCTX210, the therapy is designed to not be recognized by the immune system. It’s currently being evaluated for safety and tolerability in an early-stage clinical trial that began dosing in February and should produce data late this year or in 2023. Meanwhile, Vertex was cleared last week to resume a study of VX-880 that the Food and Drug Administration had recently paused. According to Vertex, the FDA claimed that the company hadn’t provided enough information  to support plans to give participants a higher dose of the therapy. Recommended Reading

  • When was Semma Therapeutics founded?

    Semma Therapeutics was founded in 2015.

  • Where is Semma Therapeutics's headquarters?

    Semma Therapeutics's headquarters is located at 100 Technology Square, Cambridge.

  • What is Semma Therapeutics's latest funding round?

    Semma Therapeutics's latest funding round is Acquired.

  • How much did Semma Therapeutics raise?

    Semma Therapeutics raised a total of $163M.

  • Who are the investors of Semma Therapeutics?

    Investors of Semma Therapeutics include Vertex Pharmaceuticals, ARCH Venture Partners, Medtronic, MPM Capital, F-Prime Capital and 8 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.